These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 19757993

  • 1. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 study group.
    Clin Infect Dis; 2009 Oct 15; 49(8):1259-67. PubMed ID: 19757993
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM, EASIER ANRS 138 Study Group.
    J Antimicrob Chemother; 2011 Sep 15; 66(9):2099-106. PubMed ID: 21712241
    [Abstract] [Full Text] [Related]

  • 3. Short communication: Effectiveness at 48 weeks of switching from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV type 1-infected patients in a Brazilian cohort.
    Westin MR, Biscione F, Ribeiro KM, Greco DB, Tupinambás U.
    AIDS Res Hum Retroviruses; 2014 Feb 15; 30(2):113-7. PubMed ID: 23875625
    [Abstract] [Full Text] [Related]

  • 4. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group.
    N Engl J Med; 2003 May 29; 348(22):2175-85. PubMed ID: 12637625
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, Martin-Iguacel R, Caum C, Podzamczer D, Clotet B.
    HIV Clin Trials; 2009 May 29; 10(6):432-8. PubMed ID: 20133273
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug 29; 17(96):135-7. PubMed ID: 19480091
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G, ANRS 139 TRIO Trial Group.
    Clin Infect Dis; 2009 Nov 01; 49(9):1441-9. PubMed ID: 19814627
    [Abstract] [Full Text] [Related]

  • 10. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.
    Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR.
    J Clin Virol; 2009 Dec 01; 46(4):305-8. PubMed ID: 19819183
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.
    Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M.
    J Acquir Immune Defic Syndr; 2009 Aug 01; 51(4):367-73. PubMed ID: 19487951
    [Abstract] [Full Text] [Related]

  • 13. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.
    Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM, ANRS 138 EASIER Study Group.
    J Infect Dis; 2013 Sep 01; 208(6):892-7. PubMed ID: 23801606
    [Abstract] [Full Text] [Related]

  • 14. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J, Alliance Study Group.
    Antivir Ther; 2006 Sep 01; 11(4):409-19. PubMed ID: 16856614
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.